SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the ...

Beeline Medicines has formally launched with $300 million in Series A financing, led by Bain Capital, and a pipeline of drugs for immunology and inflammation therapies licensed from Bristol Myers ...

Neomorph是一家美国蛋白质降解剂研发商，公司正在建立一个蛋白质降解实体，专注于“分子胶”降解剂。靶向蛋白质降解为在包括肿瘤学在内的各种疾病领域开发新型疗法提供了机会。近日 ...

2026年4月，美国蛋白质降解剂研发商Neomorph宣布完成1亿美元B轮融资。本轮融资由Deerfield Management领投，新增投资者包括Regeneron Ventures、Longwood Fund、Alexandria Venture Investments及Binney Street Capital。

San Diego startup Neomorph on Monday announced a new $100 million investment for its molecular glue that tricks cancer cells into self-destructing. Even as it awaits results from its first clinical ...

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement ...

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement ...

This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it's putting that claim to the test. After attracting global attention from ...

A molecular glue designed to make cancer cells self-destruct has now entered human testing for kidney cancer. (). A San Diego biotechnology company claims its molecular glue can prompt cancer cells to ...

Initiation of trial marks first-in-human milestone for Neomorph's novel molecular glue degrader platform SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering ...